| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |